The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwNHL 2018 | CAR T-cells in lymphoma: where are we now?
CAR T-cells are a hot topic right now, with huge potential for transforming the treatment of various hematological malignancies, including lymphoma. Here, David Maloney, MD, PhD, of the Fred Hutchinson Cancer Research Center, Seattle, WA, chairs a discussion on the current landscape of CAR T-cell therapy in lymphoma at the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2018 meeting, held in Nice, France. They are joined by James Kochenderfer, MD, from the National Cancer Institute, Rockville, MD, Steve Schuster, MD, from the University of Pensylvania, Philadelphia, PA, and William Go, MD, PhD, from Kite Pharma Inc., Santa Monica, CA. Along with an overview of the state of CAR T-cell therapy today, the group discuss the current standards for treatment and the avoidance of toxicities, such as neurotoxicity and cytokine release syndrome, and specific targets for this cellular therapy.
